BR0214649A - Derivados de aminotetralina como antagonistas do receptor muscarìnico - Google Patents
Derivados de aminotetralina como antagonistas do receptor muscarìnicoInfo
- Publication number
- BR0214649A BR0214649A BR0214649-5A BR0214649A BR0214649A BR 0214649 A BR0214649 A BR 0214649A BR 0214649 A BR0214649 A BR 0214649A BR 0214649 A BR0214649 A BR 0214649A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- muscarinic receptor
- aminotetraline derivatives
- compounds
- relates
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract 3
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33667501P | 2001-12-03 | 2001-12-03 | |
| PCT/EP2002/013219 WO2003048125A1 (en) | 2001-12-03 | 2002-11-25 | Aminotetralin derivatives as muscarinic receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214649A true BR0214649A (pt) | 2004-11-03 |
Family
ID=23317154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214649-5A BR0214649A (pt) | 2001-12-03 | 2002-11-25 | Derivados de aminotetralina como antagonistas do receptor muscarìnico |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6635658B2 (enExample) |
| EP (1) | EP1453806B1 (enExample) |
| JP (1) | JP4322675B2 (enExample) |
| KR (1) | KR100668231B1 (enExample) |
| CN (1) | CN100358870C (enExample) |
| AR (1) | AR037611A1 (enExample) |
| AT (1) | ATE381541T1 (enExample) |
| AU (1) | AU2002352124A1 (enExample) |
| BR (1) | BR0214649A (enExample) |
| CA (1) | CA2469055C (enExample) |
| DE (1) | DE60224221T2 (enExample) |
| ES (1) | ES2297029T3 (enExample) |
| MX (1) | MXPA04005313A (enExample) |
| PL (1) | PL370799A1 (enExample) |
| RU (1) | RU2311408C2 (enExample) |
| WO (1) | WO2003048125A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL370799A1 (en) * | 2001-12-03 | 2005-05-30 | F.Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
| EA200500173A1 (ru) | 2002-07-08 | 2005-08-25 | Рэнбакси Лабораториз Лимитед | Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов |
| US7488748B2 (en) * | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EP1618091A1 (en) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| WO2004089900A1 (en) | 2003-04-11 | 2004-10-21 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
| EP1781300A1 (en) | 2004-07-16 | 2007-05-09 | ProteoSys AG | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| WO2006035303A1 (en) * | 2004-09-29 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006054162A1 (en) * | 2004-11-19 | 2006-05-26 | Ranbaxy Laboratories Limited | Azabicyclic muscarinic receptor antagonists |
| EP1828126A1 (en) * | 2004-12-15 | 2007-09-05 | Ranbaxy Laboratories Limited | Acid addition salts of muscarinic receptor antagonists |
| US9198897B2 (en) * | 2005-01-19 | 2015-12-01 | Neurohealing Pharmaceuticals, Inc. | Methods and compositions for decreasing saliva production |
| MX2007011453A (es) * | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
| US20080319043A1 (en) * | 2005-05-03 | 2008-12-25 | Mohammad Salman | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists |
| EP2387405A2 (en) | 2009-01-13 | 2011-11-23 | ProteoSys AG | Pirenzepine as an agent in cancer treatment |
| NZ716598A (en) * | 2012-11-20 | 2017-02-24 | Merial Inc | Anthelmintic compounds and compositions and method of using thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3718317A1 (de) * | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| CA1331191C (en) | 1988-03-25 | 1994-08-02 | Bengt Ronny Andersson | Therapeutically useful tetralin derivatives |
| FR2659323B1 (fr) | 1990-03-07 | 1992-06-12 | Synthelabo | Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique. |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| AU717431B2 (en) * | 1996-07-01 | 2000-03-23 | Schering Corporation | Muscarinic antagonists |
| ATE227708T1 (de) * | 1996-07-10 | 2002-11-15 | Schering Corp | 1,4-disubstituierte piperdine als muskarin- antagonisten |
| US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
| CN1187342C (zh) | 2000-05-25 | 2005-02-02 | 弗·哈夫曼-拉罗切有限公司 | 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途 |
| DE60114413T2 (de) | 2000-05-25 | 2006-07-27 | F. Hoffmann-La Roche Ag | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten |
| PL370799A1 (en) * | 2001-12-03 | 2005-05-30 | F.Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
-
2002
- 2002-11-25 PL PL02370799A patent/PL370799A1/xx not_active Application Discontinuation
- 2002-11-25 MX MXPA04005313A patent/MXPA04005313A/es active IP Right Grant
- 2002-11-25 AT AT02787797T patent/ATE381541T1/de not_active IP Right Cessation
- 2002-11-25 BR BR0214649-5A patent/BR0214649A/pt not_active IP Right Cessation
- 2002-11-25 EP EP02787797A patent/EP1453806B1/en not_active Expired - Lifetime
- 2002-11-25 DE DE60224221T patent/DE60224221T2/de not_active Expired - Lifetime
- 2002-11-25 AU AU2002352124A patent/AU2002352124A1/en not_active Abandoned
- 2002-11-25 JP JP2003549317A patent/JP4322675B2/ja not_active Expired - Fee Related
- 2002-11-25 WO PCT/EP2002/013219 patent/WO2003048125A1/en not_active Ceased
- 2002-11-25 ES ES02787797T patent/ES2297029T3/es not_active Expired - Lifetime
- 2002-11-25 KR KR1020047008423A patent/KR100668231B1/ko not_active Expired - Fee Related
- 2002-11-25 CA CA2469055A patent/CA2469055C/en not_active Expired - Fee Related
- 2002-11-25 CN CNB028240170A patent/CN100358870C/zh not_active Expired - Fee Related
- 2002-11-25 RU RU2004120558/04A patent/RU2311408C2/ru not_active IP Right Cessation
- 2002-12-02 US US10/308,092 patent/US6635658B2/en not_active Expired - Fee Related
- 2002-12-02 AR ARP020104638A patent/AR037611A1/es not_active Application Discontinuation
-
2003
- 2003-06-27 US US10/608,604 patent/US6806278B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE381541T1 (de) | 2008-01-15 |
| DE60224221T2 (de) | 2008-12-11 |
| US20030171362A1 (en) | 2003-09-11 |
| JP2005518368A (ja) | 2005-06-23 |
| ES2297029T3 (es) | 2008-05-01 |
| US6806278B2 (en) | 2004-10-19 |
| CN100358870C (zh) | 2008-01-02 |
| CA2469055A1 (en) | 2003-06-12 |
| PL370799A1 (en) | 2005-05-30 |
| KR20050044641A (ko) | 2005-05-12 |
| WO2003048125A1 (en) | 2003-06-12 |
| CA2469055C (en) | 2011-03-29 |
| RU2004120558A (ru) | 2005-07-20 |
| EP1453806A1 (en) | 2004-09-08 |
| US20040092604A1 (en) | 2004-05-13 |
| KR100668231B1 (ko) | 2007-01-16 |
| EP1453806B1 (en) | 2007-12-19 |
| CN1639124A (zh) | 2005-07-13 |
| MXPA04005313A (es) | 2004-09-13 |
| AR037611A1 (es) | 2004-11-17 |
| JP4322675B2 (ja) | 2009-09-02 |
| DE60224221D1 (de) | 2008-01-31 |
| US6635658B2 (en) | 2003-10-21 |
| RU2311408C2 (ru) | 2007-11-27 |
| AU2002352124A1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0109235A (pt) | Derivados do ácido carboxìlico como antagonistas ip | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| BR0111263A (pt) | Derivados de 2-aminocarbonil-9h-purina | |
| BR0315317A (pt) | 4-piperazinil benzenossulfonil indóis com afinidade para o receptor de 5-ht6 | |
| BR0209267A (pt) | Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf) | |
| BR0307406A (pt) | Indóis substituìdos como agonistas alfa-1 | |
| BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
| BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
| CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
| SE9904508D0 (sv) | New compounds | |
| BRPI0406717A (pt) | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção | |
| NO20045486L (no) | Nye forbindelser og deres anvendelse | |
| YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
| BR0115291A (pt) | Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip | |
| BR0212069A (pt) | Agentes antidiabéticos orais | |
| BR0214674A (pt) | Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico | |
| BR0214695A (pt) | Derivados de pirazol com anel fundido | |
| MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| BR0009561A (pt) | 1,4-didro indeno [1,2-c] pirazóis substituìdos como inbidores de tirosina cinase | |
| BR0207795A (pt) | Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |